Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Phase III VIALE-A study showed Venclexta/Venclyxto plus azacitidine helped people with the most common type of aggressive leukaemia in adults live longer compared to azacitidine alone Data will be shared with global health authorities and presented at an upcoming medical meeting Basel, 23 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that... Read more